top of page

Learning about molecular glues from the CEO of Orionis Biosciences following a recent Genentech deal

Niko Kley explains the concept of allosteric molecular glues, and how Orionis is also trying to design cytokines that are selectively activated at the site of tumors.



Comentários


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page